DK3200785T3 - Behandling af paroxysmal ekstrem smertelidelse - Google Patents

Behandling af paroxysmal ekstrem smertelidelse Download PDF

Info

Publication number
DK3200785T3
DK3200785T3 DK15790624.9T DK15790624T DK3200785T3 DK 3200785 T3 DK3200785 T3 DK 3200785T3 DK 15790624 T DK15790624 T DK 15790624T DK 3200785 T3 DK3200785 T3 DK 3200785T3
Authority
DK
Denmark
Prior art keywords
treatment
pain relief
extreme pain
paroxysmal extreme
paroxysmal
Prior art date
Application number
DK15790624.9T
Other languages
English (en)
Inventor
Valerie Morisset
Original Assignee
Convergence Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals filed Critical Convergence Pharmaceuticals
Application granted granted Critical
Publication of DK3200785T3 publication Critical patent/DK3200785T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15790624.9T 2014-10-03 2015-10-02 Behandling af paroxysmal ekstrem smertelidelse DK3200785T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1417500.4A GB201417500D0 (en) 2014-10-03 2014-10-03 Novel use
PCT/GB2015/052887 WO2016051196A1 (en) 2014-10-03 2015-10-02 Paroxysmal extreme pain disorder treatment

Publications (1)

Publication Number Publication Date
DK3200785T3 true DK3200785T3 (da) 2019-09-16

Family

ID=51946797

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15790624.9T DK3200785T3 (da) 2014-10-03 2015-10-02 Behandling af paroxysmal ekstrem smertelidelse

Country Status (15)

Country Link
US (2) US10493059B2 (da)
EP (1) EP3200785B1 (da)
CY (1) CY1122422T1 (da)
DK (1) DK3200785T3 (da)
ES (1) ES2747824T3 (da)
GB (1) GB201417500D0 (da)
HR (1) HRP20191908T1 (da)
HU (1) HUE049392T2 (da)
LT (1) LT3200785T (da)
PL (1) PL3200785T3 (da)
PT (1) PT3200785T (da)
RS (1) RS59683B1 (da)
SI (1) SI3200785T1 (da)
SM (1) SMT201900724T1 (da)
WO (1) WO2016051196A1 (da)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
JP2897959B2 (ja) 1988-05-20 1999-05-31 エフ.ホフマン―ラ ロシュ アクチェンゲゼルシャフト 固定化された配列特異的プローブ
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
BR9607035A (pt) 1995-02-13 1997-11-04 Searle & Co Isoxazois substituidos para o tratamento de inflamação
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
ATE233743T1 (de) 1996-04-12 2003-03-15 Searle & Co N-((4-(5-methyl-3-phenylisoxazol-4- yl)phenyl)sulphonylpropylamid und sein natriumsalz als pro-pharmakon von cox-2 inhibitoren
US5866336A (en) 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
IL127441A (en) 1996-07-18 2003-02-12 Merck Frosst Canada Inc Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
DK1032575T3 (da) 1997-09-05 2003-10-20 Glaxo Group Ltd 2,3-diaryl-pyrazol(1,5-b)pyridazinderivater, deres fremstilling og anvendelse som cyclooxygenase 2 (COX-2) inhibitor
US7223772B1 (en) 1998-11-03 2007-05-29 Smithkline Beecham Corporation Pyrazolopyridine derivatives as selective cox-2 inhibitors
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
ATE261444T1 (de) 1999-02-27 2004-03-15 Glaxo Group Ltd Pyrazolopyridine
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP2117538A1 (en) * 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
US8327349B2 (en) * 2008-07-11 2012-12-04 Internationanl Business Machines Corporation Matching plug-ins to users
CA2939549C (en) * 2013-03-15 2020-08-18 Purdue Pharma L.P. Carboxamide derivatives and use thereof

Also Published As

Publication number Publication date
PL3200785T3 (pl) 2021-01-25
SI3200785T1 (sl) 2020-06-30
HUE049392T2 (hu) 2020-09-28
RS59683B1 (sr) 2020-01-31
ES2747824T3 (es) 2020-03-11
US10493059B2 (en) 2019-12-03
EP3200785B1 (en) 2019-07-31
PT3200785T (pt) 2019-09-19
WO2016051196A1 (en) 2016-04-07
CY1122422T1 (el) 2021-01-27
US20170304265A1 (en) 2017-10-26
HRP20191908T1 (hr) 2020-04-03
SMT201900724T1 (it) 2020-03-13
US20200147041A1 (en) 2020-05-14
LT3200785T (lt) 2019-09-25
EP3200785A1 (en) 2017-08-09
GB201417500D0 (en) 2014-11-19

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL269371A (en) Treatment methods
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
PL3265053T3 (pl) Sposoby leczenia skóry
DK3171928T3 (da) Stimulationsmønstre til behandling af tørt øje
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
PL3283527T3 (pl) Leczenie skojarzone nowotworów
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3231444T3 (da) Ny behandling
PL3197456T3 (pl) Leczenie nowotworów
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
EP3215219C0 (en) SKIN TREATMENT SYSTEM
EP3375108A4 (en) SELECTIVE WIFI
DK3307267T3 (da) Behandling af multipel sklerose
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
PL3134119T3 (pl) Leczenie nowotworu
HUE046894T2 (hu) Anamorelinen alapuló gyógyászati kezelések
EP3597225A4 (en) TREATMENT PROCESS
IL254825A0 (en) Methods of treatment with taselisib
IL256111B1 (en) Pac–1 combination therapy
DK3151814T3 (da) Behandling af en hudlæsion
IL246558A0 (en) Novel methods for treating cancer
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
DK3209295T4 (da) Fremgangsmåder til behandling af øjenlidelser